O, respectively. These radioisotopes are special because of their decay by positron emission and their short half-life ( 11 C, 20 min; 13 N, 10 min; 15 O, 2 min). Therefore, the production of the radionuclides (for which a cyclotron is needed) and their introduction into the desired molecules has to be performed at the place of application [usually a hospital; note that cyclotrons generate a large amount of dangerous ionizing radiation and have to be operated behind heavy shielding (9) ].
In a cyclotron, ions of hydrogen, deuterium, or helium are accelerated in a vacuum chamber by an electric field, while their path of movement is controlled by a magnetic field. As the particles reach the energy required for the chosen nuclear reaction, the particles are extracted from the vacuum chamber and deflected to hit a target, which contains the material to be converted into the desired radionuclide. Thus To enable the study of longer biological processes and transportation of the labeled products to neighboring institutes, 18 F (half-life ~ 2 h) is also used in addition to the veryshort-lived natural elements. In many molecules, it is possible to replace a hydrogen atom or a hydroxyl group with fluorine without changing the pertinent biological properties.
PET: some theoretical background
Positron emission enables tomographic imaging (PET), the dynamic registration of the radioactivity distribution in the body (10, 12) . A positron is a particle with the same mass as the electron but with a positive electric charge. After being emitted from the atomic nucleus, it has to lose its kinetic energy, and then it combines with an electron. Both particles are annihilated, emitting two 511-keV gamma radiations in opposite (180q) directions. If in two detectors placed opposite each other a 511-keV gamma is registered at the same time (coincident), an annihilation must have occurred on the line connecting the detectors (Fig. 1) . If many detectors are arranged in rings, forming a cylinder, the events can be registered in three dimensions. From these data, the spatial distribution of the radioactivity in the body can be reconstructed by using appropriate computer algorithms.
Radiation is absorbed by tissue according to its mass. By taking this into account, the measured radioactivity can be quantified. The absorption can be determined by a special measurement in the PET scanner or by computer tomography (CT). Now these measurements can be taken in a new, combined PET-CT apparatus, which as an added bonus enables an improved fusion of morphology (CT) and biochemical and physiological function (PET).
Dynamic data can be collected in specific biological (sub)structures (regions of interest) by recording the radioactivity over time. To describe the supply (input function) of the compound studied, the concentration in arterial blood is measured. Comparison of these regional time activity curves with theoretical models allows the calculation of biological functions like oxygen consumption or sugar metabolism, depending on the applied molecule. This procedure is known as pharmacokinetic modeling (2) and requires detailed knowledge about physiology and metabolism of the applied tracer molecule. Because only the absolute radioactivity in the target tissue is measured, it must be determined if the radioactivity is associated with the intact applied substance or with its metabolites. This is done by rapid chemical analysis (high-performance liquid chromatography) of blood and (if possible) Tracer technology makes it possible to observe physiological and biochemical processes in the living organism in a dynamic mode. Positron emission tomography adds the use of chemically unchanged biomolecules and of quantification. This opens up fascinating possibilities for both fundamental research and routine diagnostic applications.
tissue samples. Quantitative evaluation becomes mostly impossible if metabolites are also taken up by the target organ or if metabolism in the target organ occurs. Because of the limited precision of the PET measurements, only a small number of parameters can be calculated from the data. Thus usually a two-or three-compartment model is used, which is mostly a considerable simplification of the actual biological process.
Production of molecules used with PET
The time available for the labeling of PET molecules (including purification and quality control) is very limited: a procedure taking three half-lifes already requires an eightfold amount of radioactive starting material. Together with the negligible mass of even large amounts of radioactivity, this requires extremely fast chemical reactions and procedures. Thus it is just possible to synthesize relatively complicated organic molecules from 11 C for on-the-spot use (three half-lifes is 1 h!), but 13 N and 15 O can only be used in simple molecules. 15 O compounds are preferentially made continuously and diverted for intravenous injection as required. The time for the in vivo studies is limited for the same reason.
PET in routine clinical diagnosis
Only a few PET radiopharmaceuticals are used everywhere (15 (Fig. 2) .
In cells with increased energy consumption [e.g., brain, the surviving cells in ischemic heart tissue (17)], sugar is used as the main fuel, because it needs less oxygen to burn than fatty acids. If the myocardial uptake of [ 18 F]FDG is less than normal, this may be caused by decreased blood flow (e.g., in ischemia, the sugar metabolism is still high relative to blood flow but is lower than normal in absolute terms; redress of perfusion restores the cells) or by a complete blockage of the blood flow (e.g., infarct, in which part of the heart cells are dead). Combination with a myocardial perfusion measurement gives the answer and indicates the way of treatment (1). (Fig. 3) . L-[ 
Biological applications
In principle, any function in the body could be studied with an appropriately labeled (PET) molecule. In practice, only relatively small molecules, which can be labeled by well-defined organic chemistry methods, are used because of the necessity to (get to) know the physiology and biochemistry of the PET tracer and built in radionuclide. Another prerequisite is that the molecule concentrates in the target organ to such an extent that it is visible over the background. This means that the function to be measured must be concentrated in a welldefined region of interest, an organ or a specific organ region.
In the body, many physiological processes are activated by the binding of an activating molecule (agonist) to a biochemical structure (receptor). The biochemical structure is changed, and this movement initiates a cascade of events. An antagonist binds with high affinity to the receptor but without activation of the physiological process. If the affinity of the antagonist is higher than that of the agonist, the physiological process is (partially) blocked. Receptor-binding substances (ligands) labeled with positron-emitting radionuclides (especially antagonists) can thus be used to visualize and quantify receptors (13) . Many receptors are found in the central nervous system, but in the rest of the body many biochemical and physiological processes are also activated by receptors. The identification of the receptors is done by showing that specific molecules bind to these structures. Most receptors are groups of related biochemical structures (subtypes), and the identification of every subtype requires a specific ligand. Ligands labeled with PET isotopes enable in vivo research of the receptors and eventually diagnosis of neurodegenerative (and other) diseases.
Thus we have labeled the enantiomers of epibatidine and homoepibatidine with 11 C (6, 7). These compounds are analogous agonists for a specific subtype of the neuronal nicotinic acetylcholine receptor, which is mainly concentrated in the thalamus. The blockade of the uptake in the thalamus by cytisine, a ligand specific for this subtype, shows the specificity of the binding. Figure 4 illustrates the remarkable selectivity of the receptor: only the ()enantiomer binds with high affinity.
Outlook
Of rapidly growing interest is the use of PET technology for the development of new drugs (3) . Pharmacokinetic studies of new pharmaceuticals are greatly simplified by PET. It is possible to measure the time-dependent biodistribution of a new drug (labeled with a PET isotope) in vivo in one experiment. The effect of a drug on relevant physiological processes (e.g., blood flow, energy metabolism, receptor activation) can be made visible in vivo. Thus the number of animal experiments required to study a new pharmaceutical can be reduced dramatically.
In conclusion, the PET methodology visualizes in vivo biochemical and physiological processes, which opens up fascinating possibilities for basic research and for new, noninvasive medical diagnostics.
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